Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda. by Abaasa, Andrew et al.
Ruzagira, E; Wandiembe, S; Abaasa, A; Bwanika, AN; Bahemuka,
U; Amornkul, P; Price, MA; Grosskurth, H; Kamali, A (2011) HIV
Incidence and Risk Factors for Acquisition in HIV Discordant Cou-
ples in Masaka, Uganda: An HIV Vaccine Preparedness Study. PLoS
One, 6 (8). e24037. ISSN 1932-6203
Downloaded from: http://researchonline.lshtm.ac.uk/18675/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
HIV Incidence and Risk Factors for Acquisition in HIV
Discordant Couples in Masaka, Uganda: An HIV Vaccine
Preparedness Study
Eugene Ruzagira1*, Symon Wandiembe1, Andrew Abaasa1, Agnes N. Bwanika1, Ubaldo Bahemuka1,
Pauli Amornkul2, Matthew A. Price2, Heiner Grosskurth1,3, Anatoli Kamali1,3
1Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) Uganda Research Unit on AIDS, Entebbe, Uganda, 2 International AIDS Vaccine Initiative, New
York, New York, United States of America, 3 London School of Hygiene and Tropical Medicine, London, United Kingdom
Abstract
Objectives: To determine the incidence of and risk factors for HIV acquisition in a cohort of HIV-uninfected partners from
HIV discordant couples in Masaka, Uganda, and to establish its suitability for HIV vaccine trials.
Methods: HIV-uninfected adults living in HIV discordant couple relationships were enrolled and followed for 2 years.
Interviews, medical investigations, HIV counseling and testing, syphilis and urine pregnancy (women) tests were performed
at quarterly visits. Sexual risk behaviour data were collected every 6 months.
Results: 495 participants were enrolled, of whom 34 seroconverted during 786.6 person-years of observation (PYO). The
overall HIV incidence rate [95% confidence interval (CI)] was 4.3 [3.1–6]; and 4.3 [2.8–6.4] and 4.4 [2.5–8] per 100 PYO in men
and women respectively. Independent baseline predictors for HIV acquisition were young age [18–24 (aRR = 4.1, 95% CI 1.6–
10.8) and 25–34 (aRR = 2.7, 95% CI 1.2–5.8) years]; alcohol use (aRR = 2.6, 95% CI 1.1–6); and reported genital discharge
(aRR = 3.4, 95% CI 1.6–7.2) in the past year. Condom use frequency in the year preceding enrolment was predictive of a
reduced risk of HIV acquisition [sometimes (aRR = 0.4, 95% CI 0.2–0.8); always (aRR = 0.1, 95% CI 0.02–0.9)]. In the follow-up
risk analysis, young age [18–24 (aRR = 6.2, 95% CI 2.2–17.3) and 25-34 (aRR = 2.3, 95% CI 1.1–5.0) years], reported genital
discharge (aRR = 2.5, 95% CI 1.1–5.5), serological syphilis (aRR 3.2, 95% CI 1.3–7.7) and the partner being ART naı¨ve
(aRR = 4.8, 95% CI 1.4–16.0) were independently associated with HIV acquisition. There were no seroconversions among
participants who reported consistent condom use during the study.
Conclusions: The study has identified important risk factors for HIV acquisition among HIV discordant couples. HIV-
uninfected partners in discordant couples may be a suitable population for HIV vaccine efficacy trials. However, recent
confirmation that ART reduces heterosexual HIV transmission may make it unfeasible to conduct HIV prevention trials in this
population.
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Introduction
HIV/AIDS continues to be a significant global health problem.
Sub-Saharan Africa remains the most affected region with
heterosexual intercourse being the main mode of HIV transmission
[1]. A large proportion of new HIV infections in sub-Saharan Africa
occur within stable HIV discordant heterosexual couples [2,3,4,5,6],
and, HIV discordance is highly prevalent in diverse populations [7,8].
The high prevalence of HIV discordance and the high rates of
HIV transmission within discordant couples make them a
potentially suitable population for clinical trials evaluating
preventive vaccines, microbicides, pre-exposure prophylaxis and
other HIV prevention interventions in Africa [6,8]. Before such
trials are conducted, preparatory studies are needed to estimate
HIV incidence and assess feasibility of recruiting and retaining
volunteers for the duration of a trial [9]. Such data are also
required to support trial design and sample size estimation and the
selection of the most appropriate populations [10].
We report the incidence of and risk factors for HIV acquisition
in a cohort of HIV-uninfected partners from HIV discordant
couples enrolled in an HIV vaccine trial feasibility study. The
study was part of a set of HIV vaccine preparedness studies (VPS)
conducted by the Medical Research Council (MRC)/Uganda
Virus Research Institute (UVRI) Uganda Research Unit on AIDS
in collaboration with the International AIDS Vaccine Initiative
(IAVI) in Masaka district, Uganda.
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Methods
Ethics statement
The VPS study protocol was reviewed and approved by the
Science and Ethics Committee of the Uganda Virus Research
Institute and by the Uganda National Council for Science and
Technology. Couples were given the informed consent document
to read or, if illiterate, it was read to them by a study nurse in the
presence of an independent witness. The study nurse answered
any questions raised by the couple before obtaining written
informed consent from the HIV-uninfected partner. Later in the
study, written informed consent was also obtained from HIV-
infected partners to enable collection of data on receipt of
antiretroviral therapy (ART). Informed consent discussions were
repeated during follow up visits with both partners to ensure
continued understanding of the study. Free condoms were offered
throughout the duration of the study. Counseling on male medical
circumcision was initiated later on in the study after evidence that
this intervention was effective became available. Participants who
wished to be circumcised were referred to hospitals with surgical
facilities in Masaka district. Couples were also provided with free
outpatient medical care including diagnosis and treatment of
RTIs. HIV-infected partners were given daily trimethoprim-
sulphamethoxazole for prophylaxis against opportunistic infections
and had CD4/CD8 T-cell counts measured at study entry and
every 6 months throughout the study. Consistent with the 2003
national ART guidelines [11], HIV-infected partners whose CD4
cell counts fell below 200/mm3 and those who developed an
AIDS-defining illness were referred to and initiated ART at no
cost at specialised centres in Masaka. Referrals were also made for
other HIV related care and prevention of mother-to-child HIV
transmission (PMTCT) services. Seroconverters were also referred
to receive support and care, and offered participation in an
ongoing acute HIV infection study.
Study population
Study participants were HIV-uninfected individuals living in
discordant couple relationships (one spouse being HIV-uninfected
and the other HIV-infected). Couples suspected or already
confirmed to be HIV discordant were referred for screening from
three sources: (i) the MRC/UVRI home-based HIV voluntary
counseling and testing (VCT) service, (ii) the MRC/UVRI clinic-
based HIV VCT service, and (iii) major HIV care and VCT
providers in Masaka district.
Enrollment was offered to healthy HIV-uninfected individuals
aged 18–60 years, who were married to or cohabiting with an
HIV-infected sexual partner, willing to give informed consent and
provide locator information, be followed for 2 years, complete
interviewer administered questionnaires on HIV risk factors,
undergo repeated HIV counseling and testing, accept to receive
and share their HIV results with their partner, and for females to
be tested for pregnancy every 3 months.
Study procedures
Screening procedures consisted of: provision of study informa-
tion to the couples, obtaining informed consent from the HIV-
uninfected partners, couples’ HIV voluntary counseling and
testing (CVCT), and study eligibility assessment. Upon enrolment,
demographic and sexual risk data including data on reported
symptoms of reproductive tract infections (RTIs), extramarital sex,
condom use frequency and alcohol consumption were collected
using a structured questionnaire. A medical history was collected
and a complete physical examination performed. Venous blood
was drawn for HIV and syphilis serology. Genital examinations
were only conducted on participants who reported symptoms of
RTIs. Data collection on receipt of antiretroviral therapy (ART)
by the HIV-infected partners was initiated later in the study.
Detailed locator information including telephone numbers for
those who owned or had access to a phone was collected.
Participants were issued with study identification cards on which
scheduled study visit dates were recorded. Costs for time and
travel were reimbursed.
Couples were followed at 3-month intervals for 2 years. At each
follow up visit, CVCT was performed. On this occasion, study
participants were asked about their recent medical history, and a
symptom directed physical examination was performed. Speci-
mens were collected and laboratory tests conducted as during the
enrolment visit. Sexual risk behavior data were collected every 6
months. Interim visits were conducted for: (i) administrative
reasons; (ii) HIV VCT for presumed exposure to HIV; (iii)
obtaining laboratory test results from previous visits; (iv)
assessment and treatment of illnesses; (v) and other reasons as
requested by the participant and in response to tracing efforts.
Locator information was updated as necessary.
Participants who missed study visits were reminded to come for
follow up within 2 days of the missed visit by a community
mobiliser. At least 2 reminder visits were conducted for each
missed visit. Participants who failed to attend follow up visits
without clear reason despite the reminders, and those that could
not be traced were considered lost to follow up. Participants who
reported separation from or death of the HIV-infected partner
were withdrawn from study as soon as this information became
available.
Laboratory methods
Determine (Abbot Laboratories, Japan) rapid test was used to
screen for HIV antibodies. All positive test results were confirmed
by two parallel ELISAs (Vironostika Uni-Form II Ag/Ab,
BioMerieux, Netherlands and Murex HIV.2.O, Murex Biotech
Ltd., UK). Western blot (Genetic Systems, Biorad Laboratories)
was used to resolve discrepant ELISA results. HIV testing was
repeated after 2–4 weeks on a fresh specimen if the Western blot
test was indeterminate. Sero-syphilis testing was done using the
rapid plasma reagin (RPR) test (Biotec). RPR reactive specimens
were confirmed with the Treponema pallidum Haemaglutination
(TPHA) assay (Biotec). Participants were considered to have
serological syphilis infection if they tested positive for TPHA and
RPR with RPR titres of 1:4 or greater. ßhCG reagent strips
(Bayer Multistix 10SG) were used for urine pregnancy testing.
Statistical analysis
Data were recorded in MS Access and analysed in Stata 10
(StataCorp, College Station, Texas, USA). All participants who
completed at least one follow-up visit were eligible for statistical
analysis. Person-years of observation (PYO) were calculated as the
sum of the time from enrolment (baseline) to the date of the last
HIV-uninfected result, or to the estimated date of HIV infection
for each participant. Date of HIV infection was imputed as the
mid-point of the interval between the last HIV-uninfected and the
first HIV-infected result dates. Rate ratios and 95% confidence
intervals were obtained for potential risk factors using a Poisson
regression model. The purposeful selection algorithm [12] was
used for model building. All factors for which the association
attained statistical significance (P,0.1) at univariable analysis were
considered for a multivariable Poisson regression model. Sex, age
and male circumcision were included as a priori confounders.
Factors remaining significant at P,0.05 were retained in the final
model. Two models were fitted; a model for risk data collected at
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the enrolment visit (baseline risk analysis) and a more compre-
hensive model that included data collected at all study visits
including the enrolment visit (follow-up risk analysis). In the
follow-up risk analysis model, participants who reported or were
diagnosed with a potential risk factor at any visit during the period
under observation (but before HIV infection) were compared to
those that did not have that particular risk factor throughout the
study. For the purpose of identifying the effect of male
circumcision, circumcision status and gender were combined into
a composite variable with circumcised male, uncircumcised male
and female as its categories. A separate analysis based on
Turnbull’s exact interval censored maximum likelihood method
[13] as opposed to the mid-point imputation analysis described
above was also performed.
Results
Enrolment, baseline characteristics and retention
Screening and enrolment were conducted from March 2006 to
May 2007; quarterly follow up visits were completed in March
2009.
The study profile is shown in Figure 1. A total of 556 couples
identified as discordant were screened for eligibility: 495 couples
(89%) were confirmed to be HIV discordant and the HIV-
uninfected partner was enrolled into the study, 27 couples (4.9%)
were HIV discordant but the HIV-uninfected partner did not
meet one or more of the other eligibility criteria, 21 (3.8%) were
HIV concordant positive and 13 (2.3%) were HIV concordant
negative. The mean age of the study participants was 36.2 years
(SD: 9.2), most (69%) were male, 83% were married and only
about 20% had attained some secondary school education. Of
those enrolled, 482 (97.4%) participants completed at least one
follow up visit while 397 (80.2%) completed 2 years of follow up or
reached the study end point. Compared to those that completed
the study, non-completers were younger (median age of 33 vs. 36;
p,0.001), but were otherwise similar in terms of other
characteristics.
HIV incidence and baseline risk factors for HIV acquisition
Thirty-four participants seroconverted over 786.6 PYO. The
overall HIV incidence rate [95% confidence interval] was 4.3
[3.1–6]; and 4.3 [2.8–6.4] and 4.4 [2.5–8] per 100 PYO in men
and women respectively. Crude and adjusted associations between
risk factors present at baseline and HIV incidence are presented in
Table 1. Factors significantly associated with risk of HIV
acquisition at univariate analysis were young age [18–24
(RR = 4.1, 95% CI 1.6–10.7) and 25–34 (RR = 2.4, 95% CI
1.1–5.2) years], alcohol use (RR = 2.6, 95% CI 1.2–5.8), condom
use frequency [sometimes (RR = 0.4, 95% CI 0.2–0.8); always
(RR = 0.1, 95% CI 0.01–0.7)], and reported genital discharge in
the past year (RR = 3.1, 95% CI 1.6–6.1). Although not
significant, the risk of HIV acquisition was higher among
participants that were uncircumcised (men), not married but with
steady partner, reported genital ulcer disease in the past year, had
serological syphilis, and those whose HIV-infected partners were
ART naı¨ve.
Baseline factors that remained significantly associated with
increased risk of HIV acquisition at multivariate analysis were
young age [18–24 (aRR = 4.1, 95% CI, 1.6–10.8) and 25–34
(aRR = 2.7, 95% CI 1.2–5.8) years], alcohol use (aRR = 2.6, 95%
CI 1.1–6), and reported genital discharge (aRR = 3.4, 95% CI:
1.6–7.2) in the past year. Condom use frequency in the year
preceding enrolment was associated with a reduced risk of HIV
acquisition [sometimes (aRR = 0.4, 95% CI 0.2–0.8); always
(aRR = 0.1, 95% CI 0.02–0.9)]. Similar predictors of HIV
acquisition were identified with Turnbull’s exact interval censored
maximum likelihood analysis method.
Risk factors for HIV acquisition during study follow up
Crude and adjusted associations between risk factors present
during study follow up and HIV incidence are presented in
Table 2. At univariate analysis, factors that were significantly
associated with increased risk of HIV acquisition during the study
were young age [18–24 (RR = 10.0, 95% CI 3.7–26.9) and 25–34
(RR = 3.1, 95% CI 1.4–6.5) years], alcohol use (RR = 3.0, 95% CI
1.1–7.6), reported genital discharge (RR = 2.3, 95% CI 1.2–4.6),
serological syphilis (RR = 2.7, 95% CI 1.2–6.1) and the HIV-
infected partner being ART naı¨ve (RR = 5.4, 95% CI 1.7–17.9).
No seroconversions occurred among participants who reported
always using condoms during the study. The risk of HIV
acquisition was higher among participants that were uncircum-
cised (men), not married but with a steady partner, had genital
ulcer disease, and those that reported alcohol use although these
associations were not significant.
Factors that remained significantly associated with increased
risk of HIV acquisition at multivariate analysis were young age
[18–24 (aRR = 6.2; 95% CI: 2.2–17.3) and 25–34 (aRR = 2.3;
95% CI: 1.1–5.0) years], reported genital discharge (aRR = 2.5;
95% CI: 1.1–5.5), serological syphilis (aRR = 3.2; 95% CI: 1.3–
7.7) and the HIV-infected partner being ART naı¨ve (aRR = 4.8;
95% CI: 1.4–16.0). Similar predictors of HIV acquisition were
identified with Turnbull’s exact interval censored maximum
likelihood analysis method.
Discussion
The overall HIV incidence of 4.3 per 100 PYO in this cohort was
high but lower than the rates reported in previous HIV discordant
couple studies in Uganda [3,14]. These previous studies were
retrospective and conducted before ART became widely available
in Uganda. Almost one third of the HIV-infected partners of our
participants had initiated ART by the end of the study. Also, in our
study, couples underwent HIV testing and risk reduction counsel-
ing, and were offered condoms at all study visits, which is likely to
have resulted in some risk reduction. All these may help to explain
the lower HIV incidence in our cohort compared to previous
studies. Regular HIV testing and counseling is associated with
increased condom use among couples [5,15] and reduced
heterosexual transmission of HIV in HIV discordant couples [15].
As discussed further below, our findings also confirm those by others
that ART in the HIV-infected partner is associated with a decrease
in heterosexual HIV transmission among discordant couples [16].
Although we provided information on the protective effect of male
circumcision and referrals for those who wished to have the
procedure, only one participant was circumcised during the study
period. Male circumcision cannot therefore explain the relatively
low HIV incidence observed in our study.
Also, participants who dropped out of the study were younger
than those who completed it. This may have resulted in
underestimation of HIV incidence since the risk of HIV
acquisition was higher among younger participants. A higher
HIV incidence among younger people has also been documented
in previous studies [14]. This phenomenon could be due to
cervical ectopy in younger women and an increase in minor
genital trauma during intercourse among younger people [17,18].
We did not collect data on frequency of sexual intercourse;
however, frequency of intercourse in previous studies [17] did not
explain the change in risk of HIV acquisition with age.
Preparation for HIV Vaccine Trials in Rural Uganda
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We found no significant difference in HIV incidence between
men and women, the rate being about 4 per 100 PYO for each
gender. Data on gender-specific HIV transmission risk from
available literature is inconclusive. A study in the neighbouring
district of Rakai found similar HIV transmission risks among men
and women [14]. However, previous studies in Masaka [3] and
Mwanza, Tanzania [4], found that HIV incidence in women with
HIV-infected spouses was twice that of men. The reason for these
conflicting results is unclear.
Alcohol use before sexual intercourse has been associated with
increased risk of HIV acquisition in discordant couple [15] and in
general population [19] cohorts. This is attributed to alcohol
related disinhibition that results in increased risk behaviours such
as non-use of condoms [15,19]. Also, in vitro [20] and animal [21]
studies have demonstrated that alcohol may enhance susceptibility
to HIV infection through its effects on certain components of the
immune system. In our study, a baseline history of alcohol use was
associated with a nearly three-fold increase in the risk of HIV
acquisition.
As expected, we found that regular condom use was strongly
protective against HIV acquisition. Therefore, consistent condom
use for prevention of HIV transmission among discordant couples
Figure 1. Study profile.
doi:10.1371/journal.pone.0024037.g001
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Table 1. Baseline factors associated with incident HIV infection among HIV-uninfected partners in HIV discordant couples, Masaka,
Uganda.
N (%) Seroconverters PYO
Rate/
100 PYO
RR
(95% CI) LRT p-value
aRR
(95% CI)
Total 482 (100.0) 34 786.6 4.3
Male circumcision
Circumcised 93 (19.3) 3 152.5 2.0 1.0 0.21 1.0
Uncircumcised 237 (49.2) 20 386.4 5.2 2.6 (0.8-8.9) 1.6 (0.4-5.7)
Female 152 (31.5) 11 247.7 4.4 2.3 (0.6-8.1) 1.3 (0.3-4.9)
Age group
$35 260 (53.9) 11 447.9 2.5 1.0 0.01 1.0
25-34 175 (36.3) 16 269.1 5.9 2.4 (1.1-5.2) 2.7 (1.2-5.8)
18-24 47 (9.8) 7 69.6 10.1 4.1 (1.6-10.7) 4.1 (1.6-10.8)
Marital status
Married 396 (82.2) 25 646.5 3.9 1.0 0.21
Steady partner 86 (17.8) 9 140.1 6.4 1.7 (0.8-3.6)
Religious affiliation
Non Muslim 383 (79.5) 30 622.6 4.8 1.0 0.16
Muslim 99 (20.5) 4 164.0 2.4 0.5 (0.2-1.4)
Education level
$Secondary 94 (19.5) 6 151.4 4.0 1.0 0.93
Primary 338 (70.1) 25 555.2 4.5 1.1 (0.5-2.8)
None 50 (10.4) 3 80.1 3.7 0.9 (0.2-3.8)
Alcohol use
No 213 (44.2) 8 350.3 2.3 1.0 0.01 1.0
Yes 269 (55.8) 26 436.3 6.0 2.6 (1.2-5.8) 2.6 (1.1-6.0)
Extramarital sex in past year
No 310 (64.3) 21 511.3 4.1 1.0 0.69
Yes 172 (35.7) 13 275.4 4.7 1.1 (0.6-2.3)
Condom use frequency in
past year
Did not use 193 (40.0) 23 308.2 7.5 1.0 0.001 1.0
Sometimes 210 (43.6) 10 344.3 2.9 0.4 (0.2-0.8) 0.4 (0.2-0.8)
Always 79 (16.4) 1 134.2 0.7 0.1 (0.01-0.7) 0.1 (0.02-0.9)
Genital ulcer disease in
past year
No 354 (73.4) 22 585.6 3.8 1.0 0.21
Yes 128 (26.6) 12 201.0 6.0 1.6 (0.8-3.2)
Genital discharge in
the past year
No 378 (78.4) 19 626.4 3.0 1.0 0.002 1.0
Yes 104 (21.6) 15 160.2 9.4 3.1 (1.6-6.1) 3.4 (1.6-7.2)
Serological syphilis
Negative 457 (94.8) 31 745.9 4.2 1.0 0.37
Positive 25 (5.2) 3 40.7 7.4 1.8 (0.5-5.9)
Receipt of ART by
HIV-infected partner
Yes 80 (16.6) 3 138.6 2.2 1.0 0.33
No 359 (74.5) 29 612.9 4.7 2.2 (0.7-7.2)
Data not collected 43 (8.9) 2 35.1 5.7 2.6 (0.4-15.8)
PYO, person-years of observation; RR, unadjusted rate ratio; aRR, adjusted rate ratio (All factors were adjusted for gender, age group at study entry, male circumcision,
alcohol use, condom use frequency, and genital discharge in the past year); CI, confidence interval; LRT, likelihood ratio test.
doi:10.1371/journal.pone.0024037.t001
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in stable unions should be strongly promoted [15,22]. However,
our observation also confirms that in spite of the regular and
intensive health education and condom promotion that we
provided during the study, the acceptability and use of condoms
in marriage or stable partnerships is low even among couples who
are well informed about each other’s HIV status. At least two
reasons may be responsible for this: the fact that in Africa
traditionally condoms have been associated with infidelity and
Table 2. Risk factors for incident HIV infection during follow up among HIV-uninfected partners in HIV discordant couples, Masaka,
Uganda.
N (%) Seroconverters PYO
Rate/
100 PYO
RR
(95% CI)
LRT
p-value
aRR
(95% CI)
Total 482 (100.0) 34 786.6 4.3
Male circumcision
Circumcised 94 (19.5) 3 154.3 1.9 1.0 0.20 1.0
Uncircumcised 236 (49.0) 20 384.6 5.2 2.7 (0.8-9.0) 2.7 (0.8-9.2)
Female 152 (31.5) 11 247.7 4.4 2.3 (0.6-8.2) 2.0 (0.5-7.7)
Age group
$35 293 (60.8) 11 504.0 2.2 1.0 0.001 1.0
25-34 166 (34.4) 17 255.0 6.7 3.1 (1.4-6.5) 2.3 (1.1-5.0)
18-24 23 (4.8) 6 27.6 21.7 10.0 (3.7-26.9) 6.2 (2.2-17.3)
Education
$Secondary 94 (19.5) 6 151.4 4.0 1.0 0.93
Primary 338 (70.1) 25 555.2 4.5 1.1 (0.5-2.8)
None 50 (10.4) 3 80.1 3.7 0.9 (0.2-3.8)
Religion
Non Muslim 383 (79.5) 30 622.6 4.8 1.0 0.16
Muslim 99 (20.5) 4 164.0 2.4 0.5 (0.2-1.4)
Marital Status
Married 396 (82.2) 25 646.5 3.9 1.0 0.21
Steady partner 86 (17.8) 9 140.1 6.4 1.7 (0.8-3.6)
Alcohol use
No 162 (33.6) 5 265.6 1.9 1.0 0.01
Yes 320 (66.4) 29 521.1 5.6 3.0 (1.1-7.6)
Extramarital sex
No 270 (56.0) 19 445.2 4.3 1.0
Yes 212 (44.0) 15 341.5 4.4 1.03 (0.5-2.0) 0.93
Condom use frequency
Sometimes 454 (94.2) 34 735.8 4.6 - -
Always 28 (5.8) 0 50.9 0.0 - -
Reported genital ulcer
No 305 (63.3) 17 502.4 3.4 1.0 0.10
Yes 177 (36.7) 17 284.2 6.0 1.8 (0.9-3.5)
Reported genital discharge
No 323 (67.0) 16 531.9 3.0 1.0 0.01 1.0
Yes 159 (33.0) 18 254.7 7.1 2.3 (1.2-4.6) 2.5 (1.1-5.5)
Serological syphilis
Negative 438 (90.9) 27 717.0 3.8 1.0 0.04 1.0
Positive 44 (9.1) 7 69.6 10.1 2.7 (1.2-6.1) 3.2 (1.3-7.7)
Receipt of ART by HIV-infected
partner
Yes 152 (31.5) 3 270.6 1.1 1.0 0.002 1.0
No 287 (59.5) 29 480.9 6.0 5.4 (1.7-17.9) 4.8 (1.4-16.0)
Data not collected 43 (8.9) 2 35.1 5.7 5.1 (0.9-30.7) 3.9 (0.6-23.8)
PYO, person-years of observation; RR, unadjusted rate ratio; aRR, adjusted rate ratio (All factors were adjusted gender, age group at study exit, male circumcision,
reported genital discharge, serological syphilis and ART use in the HIV-infected partner); CI, confidence interval; LRT, likelihood ratio test.
doi:10.1371/journal.pone.0024037.t002
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prostitution and are therefore stigmatized [23]; and the strong
desire of married couples to have children [5,24].
Treatable RTIs are common and important correlates of HIV
transmission within discordant heterosexual couples [25]. History
of genital discharge and sero-syphilis diagnosis during the current
study were each independently associated with an increased risk of
HIV acquisition.
Though only borderline significant, the risk of HIV acquisition
was higher among uncircumcised compared to circumcised men.
Recent randomized clinical trials [26,27] have provided compel-
ling evidence that male circumcision significantly reduces the risk
of HIV acquisition in heterosexual men. Once policies on male
circumcision are in place and services rolled out, the effect of male
circumcision on HIV incidence should be taken into account for
sample size estimations in future HIV prevention trials. Even
where such services are not available yet, it is likely to become an
ethical condition that research projects will have to make them
available.
We found that ART initiated according to the national HIV
treatment guidelines [11] was associated with a reduced risk of
heterosexual HIV acquisition. The risk of HIV acquisition was 6.0
per 100 PYO among participants whose HIV-infected partners
were ART naı¨ve, compared to 1.1 per 100 PYO among those
whose partners were receiving ART, an 82% difference. Although
earlier observational studies [16] had also reported a reduced risk
of HIV transmission in the presence of ART, the evidence was
insufficient to formulate policy and guidance on the role of ART in
HIV prevention [28]. Conclusive evidence on the role of ART in
HIV prevention has only become recently available following the
early release of the HIV Prevention Trials Network (HPTN) 052
study results [29]. In this trial, early initiation of ART by HIV-
infected individuals substantially protected their HIV-uninfected
sexual partners from acquiring HIV infection, with a 96%
reduction in risk of HIV transmission. Findings from this trial
are expected to inform future recommendations on use of ART for
HIV prevention among discordant couples [30]. Consequently, it
may become an ethical requirement for HIV prevention research
projects involving discordant couples to provide ART to the HIV-
infected partners. It is likely that these developments will have an
impact on study design and sample size of future HIV prevention
trials; and such trials may become even more difficult should
universal testing and ART treatment strategies be shown to be
effective in reducing HIV transmission at the population level.
With the exception of ART, we did not collect data on other
risk factors among HIV-infected partners that could facilitate HIV
transmission. This was because the VPS protocol primarily
targeted HIV-uninfected individuals at high risk of HIV
acquisition. Early and late stage HIV infection, higher HIV load,
genital ulcer disease, and younger age of the HIV-infected partner
have all been associated with higher rates of HIV transmission
[31].
Enrolment of participants in the current study overlapped that
of the Microbicides Development Programme (MDP) 301 trial.
MDP301 was a multicentre phase III trial of the PRO 2000/5
vaginal gel. At our centre, the trial recruited HIV-uninfected
women who were in HIV discordant partnerships [32]. As a result,
couples referred to and enrolled in current study were predom-
inantly those in which the HIV-uninfected partner was male. We
cannot determine the extent to which this gender bias affected the
study results. Nonetheless, we believe that the findings may be
applicable to other HIV discordant couple populations.
Our study has shown that in addition to being in an HIV
discordant relationship, there are other important risk factors for
HIV transmission among HIV discordant couples that need to be
urgently targeted. The high HIV incidence and moderate
participant retention observed in this study suggest that HIV-
uninfected partners in discordant couples may be a suitable
population for phase IIb/III preventive HIV vaccine trials in our
setting. However, recent findings confirming that ART signifi-
cantly reduces HIV transmission from an infected partner to an
uninfected spouse may make it unfeasible to conduct future HIV
prevention trials in this population.
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